GLP-1 week 1 side effects: what the data actually shows
Quick answer
The creator is using semaglutide (Ozempic) for type 2 diabetes management and reports mild, transient side effects during dose initiation, consistent with the known tolerability profile established in the SUSTAIN trial program. She frames the medication as one component of a broader management strategy including diet, exercise, and blood glucose monitoring, which aligns with FDA-approved use and current ADA standards of care. Her self-injection into the thigh using a pinch technique reflects standard subcutaneous administration guidance, though she noted the presence of lotion on her skin, which is not recommended practice for injection site preparation.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @stephaniegay14 actually say?
She kept it pretty straightforward. She's on week two of Ozempic for type 2 diabetes management, describes her side effects from week one as "just a headache the first 3 days and slight GI things," and frames the medication as one tool in a broader approach: "diet, exercise, watching my blood sugar, all those good things." She then demonstrates a self-injection into her thigh, noting she had lotion on her skin from moisturizing after a shower. Her husband sat nearby for moral support. There were no dramatic claims about weight loss, no miracle framing, and no dosage advice directed at viewers. This was essentially a personal experience video, not a how-to guide, which matters when we assess what she actually put out into the world.
Does the science back this up?
The side effect profile she described is consistent with published clinical data. Headache and gastrointestinal symptoms in the first weeks of semaglutide use are well-documented and expected. Her framing of Ozempic as a management tool alongside lifestyle changes also reflects current clinical guidance accurately.
The SUSTAIN clinical trial program, particularly SUSTAIN-6 (Marso et al., 2016, NEJM), established semaglutide's efficacy in type 2 diabetes management when combined with standard care. Nausea, diarrhea, and vomiting were the most commonly reported side effects, occurring predominantly in the early weeks and at dose escalation. Headache is also reported, though less frequently than GI symptoms. Her experience of mild, transient symptoms fits the known tolerability curve for the drug.
Her "pinch the fat" injection technique is consistent with manufacturer guidance for subcutaneous administration. Injecting through recently moisturized skin is not contraindicated, though no clinical literature specifically addresses lotion as a preparation variable.
What did they get wrong (or right)?
Mostly right, with one minor practical note worth flagging. She does not get the mechanism wrong, does not overclaim benefits, and does not tell anyone to take Ozempic or at what dose. Credit where it's due: framing GLP-1 therapy as a tool alongside diet and exercise is exactly how it should be framed, and a lot of creators don't do that.
The one thing worth noting: she mentions having lotion on her legs before injecting. While this is unlikely to cause any real harm, injection site preparation typically involves clean, dry skin. The FDA prescribing information for semaglutide doesn't list lotion as a contraindication, but standard subcutaneous injection technique across drug classes recommends avoiding creams or oils at the site to prevent potential contamination or absorption interference. It's a small point, but worth knowing if you're doing this at home.
She also refers to the drug as "ozenpe" throughout, which appears to be a mispronunciation of Ozempic. This is cosmetic, not clinical, but worth noting for context.
What should you actually know?
GI side effects during GLP-1 initiation are not a reason to stop the medication without talking to your prescriber first. The SCALE and SUSTAIN trial data consistently show these effects are dose-dependent and time-limited for most patients. Davies et al. (2021, Diabetes Care) found that gradual dose escalation significantly reduces early GI burden.
If you are considering Ozempic or any semaglutide product for diabetes management, the decision belongs between you and a licensed clinician who can review your full medical history. Ozempic is FDA-approved specifically for type 2 diabetes; Wegovy contains the same active ingredient at a higher approved dose for chronic weight management. These are not interchangeable prescriptions, and compounded semaglutide products are not equivalent to FDA-approved branded medications.
- Early side effects like nausea and headache typically peak in weeks one to four and improve as your body adjusts.
- Subcutaneous injections should go into clean, dry skin, typically the abdomen, thigh, or upper arm.
- Self-injection technique matters. If you are newly starting, ask your pharmacist or prescriber to walk you through it, not just a TikTok video.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 week 1 side effects: what the data actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
GLP-1 week 1 side effects: what the data actually shows should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The creator is using semaglutide (Ozempic) for type 2 diabetes management and reports mild, transient side effects during dose initiation, consistent with the known tolerability profile established in the SUSTAIN trial program.
FormBlends verdict
The creator is using semaglutide (Ozempic) for type 2 diabetes management and reports mild, transient side effects during dose initiation, consistent with the known tolerability profile established in the SUSTAIN trial program. She frames the medication as one component of a broader management strategy including diet, exercise, and blood glucose monitoring, which aligns with FDA-approved use and current ADA standards of care. Her self-injection into the thigh using a pinch technique reflects standard subcutaneous administration guidance, though she noted the presence of lotion on her skin, which is not recommended practice for injection site preparation.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is using semaglutide (Ozempic) for type 2 diabetes management and reports mild, transient side effects during dose initiation, consistent with the known tolerability profile established in the SUSTAIN trial program. She frames the medication as one component of a broader management strategy including diet, exercise, and blood glucose monitoring, which aligns with FDA-approved use and current ADA standards of care. Her self-injection into the thigh using a pinch technique reflects standard subcutaneous administration guidance, though she noted the presence of lotion on her skin, which is not recommended practice for injection site preparation.
- In the SUSTAIN-6 trial (Marso et al., 2016, NEJM), nausea and GI symptoms affected roughly 20-40% of semaglutide users early in treatment, typically resolving with continued use and dose escalation protocols.
- Headache is a reported but less common adverse effect of semaglutide initiation; the mechanism is not fully established but may relate to reduced caloric intake and appetite suppression effects.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- In the SUSTAIN-6 trial (Marso et al., 2016, NEJM), nausea and GI symptoms affected roughly 20-40% of semaglutide users early in treatment, typically resolving with continued use and dose escalation protocols.
- Headache is a reported but less common adverse effect of semaglutide initiation; the mechanism is not fully established but may relate to reduced caloric intake and appetite suppression effects.
- Davies et al. (2021, Diabetes Care) found that slower dose escalation schedules significantly reduce early GI side effect burden without compromising long-term efficacy.
- Ozempic (semaglutide 0.5mg/1mg/2mg) is FDA-approved for type 2 diabetes management; Wegovy (semaglutide 2.4mg) is approved for chronic weight management. They are not interchangeable, and compounded semaglutide is not equivalent to either branded product.
- Subcutaneous injections should be administered into clean, dry skin. Applying lotion before injecting is not recommended practice, even if the clinical risk from a single instance is low.
- Self-injection of subcutaneous medications should be learned through a licensed clinician or pharmacist, not social media videos, to reduce technique errors and infection risk.
- GLP-1 therapy for type 2 diabetes is a chronic management strategy, not a short-term fix. Week two results, positive or negative, are not predictive of long-term outcomes.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
StephySpikesAgain💕🍭 · TikTok creator
4.5K views on this video
Hoping that week 2 is as easy as week 1! Side effects were minimal with just a headache the first 3 days and slight GI things. Very manageable and well worth the benefits! #diabetes #type2diabetes #insulinresistance #glp1 #diabetesmanagement
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by StephySpikesAgain💕🍭, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.